
Inventiva S.A. (IVA) Stock Forecast & Price Target
Inventiva S.A. (IVA) Analyst Ratings
Bulls say
Inventiva SA is a biopharmaceutical company focused on developing lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH), a condition lacking approved therapies, while also exploring a range of pre-clinical therapy programs. The improvement in metabolic markers, such as HbA1c and insulin resistance indices, alongside the potential for lanifibranor to provide fibrosis improvement, positions the drug favorably in the therapeutic landscape, especially as a complement to existing treatments like GLP-1s. Additionally, the company's strong revenue generation through partnerships with AbbVie and BI underpins a solid financial foundation, enhancing the potential for growth and adoption in the market as clinical results continue to support lanifibranor's efficacy.
Bears say
Inventiva SA, a biopharmaceutical company focused on developing treatments for non-alcoholic steatohepatitis, is currently facing a challenging financial outlook characterized by a significant net loss of €175.9 million, equating to €1.62 per share. The primary clinical program, lanifibranor, which is in Phase III development, presents considerable risks, as any issues regarding efficacy or safety could materially harm the company’s stock performance. Furthermore, the company relies heavily on research partnerships for revenue, while the overall competitive landscape in liver disease treatments reveals disappointing results for currently approved therapies, heightening concerns over Inventiva's ability to navigate future clinical and regulatory hurdles.
This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.
Inventiva S.A. (IVA) Analyst Forecast & Price Prediction
Start investing in Inventiva S.A. (IVA)
Order type
Buy in
Order amount
Est. shares
0 shares